Skip to content
Screener

Current ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.3×-1.3×
EyePoint, Inc. logo
EyePoint, Inc.EYPT
4.5×-3.5×
KLR
Kalaris TherapeuticsKLRS
12.2×-2.1×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
9.3×-3.0×
HRO
HarrowHROW
2.5×+1.6×
PVL
Palvella TherapeuticsPVLA
28.9×+20.0×

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.84B+556%
Enterprise value$2.73B+592%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

Based on the most recent quarter.

The source filing: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211951

FAQ

What is Kodiak Sciences Inc's current ratio?
Kodiak Sciences Inc (KOD) reported current ratio of 3.5× in Q1 2026.
How has Kodiak Sciences Inc's current ratio changed year-over-year?
Kodiak Sciences Inc's current ratio decreased by 23.5% year-over-year, from 4.6× to 3.5×.
What is the long-term trend for Kodiak Sciences Inc's current ratio?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's current ratio has grown at a -31.3% compound annual growth rate (CAGR), from 30.9× to 4.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Kodiak Sciences Inc's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude